ライフサイエンスコーパス: skin rash

1 discontinued treatment because of toxicity (skin rash).

2 AL-PEG (0.100 mg/kg) developed a generalised skin rash.

3 bexarotene-induced hypertriglyceremia and/or skin rash.

4 xarotene-induced hypertriglyceridemia and/or skin rash.

5 ose reductions of erlotinib due to grade 2/3 skin rash.

6 prophylactic treatment of erlotinib-induced skin rash.

7 oxicities were mild hypertriglyceridemia and skin rash.

8 is a commonly occurring, intensely pruritic skin rash.

9 tion of viremia and developed a desquamating skin rash.

10 syndrome, and two patients (5%) had grade 3 skin rash.

11 atient experienced a reactivation-associated skin rash.

12 w transplant (seroconversion, HHV-6 viremia, skin rash); 18 of 20 had increased peripheral blood mono

13 he most common grade 3-4 adverse events were skin rash (21 [27%] of 77 patients vs 20 [22%] of 92 pat

14 fever (43%), anorexia (33%), fatigue (33%), skin rash (21%), stomatitis (14%), and allergic reaction

15 pulmonary toxicity were common, and included skin rash (38%), peripheral eosinophilia (38%), liver dy

16 Other grade 3 or 4 toxicities included skin rash (4 patients, 10%), peripheral neuropathy (2 pa

17 The most common grade 3 or 4 toxicity was skin rash (45%), followed by neutropenia (21%) without f

18 itis/stomatitis (6%), constipation (6%), and skin rash (6%).

19 vae (100%), fever (100%), fatigue (87%), and skin rash (75%).

20 Percentage of common toxicities were skin rash, 86% and 72%; fatigue, 51% and 44%; and AST/AL

21 The most common adverse effects were skin rash (9.1%) and fatigue (8%).

22 Clinical features were skin rash (92%), pancytopenia (78%), and diarrhea (65%).

23 on 2 girls with periodic episodes of fever, skin rash, abdominal pain, and arthralgia, of whom 1 had

24 de female predominance, presence of fever or skin rash, absence of subcutaneous nodules or finger clu

25 Skin rash also correlated with drug levels and tended to

26 ghlights successful management of telaprevir skin rash and anal discomfort by switching to boceprevir

27 Grade 1/2 skin rash and diarrhea were the most frequent treatment-

28 ght (53%) experienced grade 1 to 2 acne-like skin rash and diarrhea, but no grade 3 or 4 toxicity occ

29 ne protected 80% of the infant macaques from skin rash and MV-induced immunosuppression.

30 1-blind MV, viremia was short-lived, and the skin rash and other clinical signs observed with wild-ty

31 All responding patients had mild (grade 1/2) skin rash and two patients had positive tumoral HER1/EGF

32 rile neutropenia, hypotension, myalgias, and skin rash and were removed from treatment more often as

33 itis, sensorineural hearing loss, urticarial skin rash, and a characteristic deforming arthropathy.

34 f emergency department visits for asthma and skin rash, and Culex quinquefasciatus species-specific v

35 en patients had normal liver function tests, skin rash, and diagnosis of GvHD histologically confirme

36 vere infantile-onset IBD, failure to thrive, skin rash, and perirectal abscesses refractory to medica

37 Sex, histology, skin rash, and smoking history predicted outcome with er

38 phenotype includes granulomatous arthritis, skin rash, and uveitis and probably represents a subtype

39 r, sterile peritonitis, arthralgia, myalgia, skin rash, and/or conjunctivitis; some patients also dev

40 ase was characterized chiefly by arthralgia, skin rashes, and AA amyloidosis.

41 , to mild infection, characterized by fever, skin rashes, and arthritis.

42 ned with the terms "psoriasis," "pustular," "skin," "rash," and "palmoplantar." All relevant articles

43 Patients experienced fever, skin rash, arthralgia and conjunctivitis.

44 The DLT was reversible hepatotoxicity and skin rash at 70 mg/m(2) per day for 5 days.

45 -4.03 [95% CI, -13.76 to 5.70]; P = .42) or skin rash (beta = -1.00 [95% CI, -6.92 to 4.92]; P = .74

46 netic disorder characterized by a congenital skin rash, birth defects of the skeleton, genomic instab

47 and hypersensitivity, diarrhea and vomiting, skin rash, clinical deterioration, and patient's wishes

48 include GI (diarrhea, anorexia, and nausea), skin rash, cytopenias, pleural effusions, and fatigue.

49 re to industrial phenolics is known to cause skin rash, dermal inflammation, contact dermatitis, leuc

50 Common adverse events were skin rash/desquamation, hand-foot skin reaction, and fat

51 The most common adverse events were skin rash, diarrhea, and fatigue.

52 Patients typically developed fever, skin rash, diarrhea, or pancytopenia within 2 to 6 weeks

53 ecipients with a clinical suspicion of GvHD (skin rash, diarrhea, pyrexia, pancytopenia, or anemia, w

54 In the rituximab group, nausea and skin rash during infusion were common; transient acute a

55 tion (three [8%]), hypertension (six [16%]), skin rash (eight [22%]), and pancreatitis (six [16%] pat

56 mptoms; however, all 3 children did manifest skin rash, fatigue, and biopsy-proven glomerulonephritis

57 Common toxicities included diarrhea, skin rash, fatigue, and hand-foot syndrome.

58 The most common adverse events were skin rash (five patients) and oedema with weight gain (s

59 n drug-related adverse events were diarrhea, skin rash, hyperglycemia, and night blindness.

60 ss, nausea, anorexia, arrhythmia, headaches, skin rash, hypotension, and neutropenia.

61 ing, and diarrhea in 2 patients, and grade 3 skin rash in 1 patient.

62 e cisplatin toxicity but was associated with skin rash in a majority of patients and occasional serio

63 treatment was interrupted because of grade 3 skin rash in four patients in the placebo arm, and none

64 dence-based trials for EGFR antibody-induced skin rash in patients with cancer.

65 ost common toxicities were anemia, acne-like skin rash, leukopenia, fatigue and malaise, and nausea a

66 Although skin rash may be a pharmacodynamic marker of drug action

67 hematologic toxicities of docetaxel included skin rashes, mucositis, and mild elevations of serum tra

68 st abnormalities, nausea/vomiting, diarrhea, skin rashes, mucositis, and palmoplantar erythrodysesthe

69 foot syndrome, diarrhea, hyperbilirubinemia, skin rash, myalgia, and arthralgia.

70 e a day (grade 3 diarrhoea [n=1] and grade 3 skin rash [n=1]).

71 in no major toxicities, including absence of skin rash observed with other EGFR-directed agents.

72 Anemia, gastrointestinal side effects, and skin rashes occurred at a higher incidence among patient

73 re supported by histologic findings from the skin rash of a human subject who received an attenuated

74 gs of inflammatory myopathy, and the typical skin rash of dermatomyositis.

75 for neutrophil transudation during colitis, skin rash or peritonitis.

76 y more frequent at contrast-enhanced CT were skin rash (P = .0311), skin redness (P = .0055), skin sw

77 Skin rash, palmar-plantar erythrodysesthesia, and thromb

78 elationship to study drug, were an acne-like skin rash, predominantly on the face and upper torso (86

79 so 2 apparent treatment failures in cases of skin rash, raising questions about the efficacy or suita

80 associated vasculitis manifested by purpuric skin rashes, renal abnormalities, and elevated cryoglobu

81 ade 3 adverse event in the AZD8931 group was skin rash (three [20%] of 15 patients with available dat

82 ranging from a single bone lesion or trivial skin rash to an explosive disseminated disease.

83 four [4%] vs two [2%] postoperatively), and skin rash (two [1%] vs 21 [15%] preoperatively; 0 vs eig

84 Free-text answers revealed themes of "Skin Rashes", "User-satisfaction" and "Empowerment".

85 Skin rash, viremia, and the strength of the innate and a

86 Erlotinib-induced skin rash was associated with improved CFS (P = .01).

87 Variability in skin rash was best explained by a multivariate logistic

88 Skin rash was observed in 21% of patients.

89 Skin rash was the most common toxicity (grade 3, 15%).

90 (> 5 days) and/or associated with fever, and skin rashes were consistently experienced by heavily (HP

91 Skin rashes were noted in four patients treated at 20 an

92 toimmune events with the early appearance of skin rashes were observed in patients with stable diseas